Figure 6.

SINGER-mediated antitumor performance of engineered VNP20009 delivered via intravenous injection in different tumor xenograft mouse models

(A) Schematic illustration of SINGER-mediated antitumor performance against B16F10_luci melanoma tumors. C57BL/6 mice bearing B16F10_luci melanoma tumors received intravenous injections of PBS, VNP20009, US, VNP20009+US, SINGER-azurin, or SINGER-azurin+US.

(B) Serial in vivo bioluminescence imaging of B16F10_luci tumors expressing luciferase in the groups described in (A).

(C) Bioluminescence quantification of B16F10_luci-tumor-bearing mice treated with different treatments.

(D) Tumor volume measurement in the indicated mouse groups.

(E) Kaplan-Meier curves for mouse survival in (B).

(F–H) Tumor volume measurement in mice bearing various xenograft tumors, including CT26 (F), A20 (G), and H22 tumors (H).

(I–K) Kaplan-Meier curves for mouse survival in (F)–(H).

Data in (C)–(K) are presented as means ± SEM; n = 4–6 mice. p values were calculated by one-way ANOVA with Tukey’s post-test (∗∗∗∗p < 0.0001).

See also Figures S8–S11.